Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Company news > 2020 > Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19 (novel coronavirus).

Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19 (novel coronavirus).

Viriom, Inc. announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19 (novel coronavirus).

Read also

#BIO2024!

#BIO2024!
Thank you to everyone who visited us at the ChemDiv, Inc. booth in the California Pavilion.

ChemDiv, Inc. is coming to #BIO2024!

ChemDiv, Inc. is coming to #BIO2024!

ChemDiv, Inc. is coming to #BIO2024! Join us at the California Pavilion booth #2625 or connect with us through the Partnering System.

ChemDiv to Participate in the EF Hutton Annual Global Conference

ChemDiv to Participate in the EF Hutton Annual Global Conference

ChemDiv, Inc, announced today that Bill Farley, CEO, will participate in the EF Hutton Annual Global Conference (https://efhutton.com/conference/). The conference is being held in person at Th...

Team ChemDiv, Inc. at AACR 2024, San Diego!

Team ChemDiv, Inc. at AACR 2024, San Diego!

Last week, our team had the incredible opportunity to attend the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.